The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the pr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Youssef, Mina M. G. [verfasserIn] Metwally, Ahmed A. [verfasserIn] Manie, Tamer M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of the Egyptian National Cancer Institute - Cairo : Inst., 2000, 33(2021), 1 vom: 08. Feb. |
|---|---|
| Übergeordnetes Werk: |
volume:33 ; year:2021 ; number:1 ; day:08 ; month:02 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43046-021-00061-9 |
|---|
| Katalog-ID: |
SPR043090869 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043090869 | ||
| 003 | DE-627 | ||
| 005 | 20230519195519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210209s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43046-021-00061-9 |2 doi | |
| 035 | |a (DE-627)SPR043090869 | ||
| 035 | |a (DE-599)SPRs43046-021-00061-9-e | ||
| 035 | |a (SPR)s43046-021-00061-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Youssef, Mina M. G. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. | ||
| 650 | 4 | |a Neoadjuvant chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Complete pathological response |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Management of axilla |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Metwally, Ahmed A. |e verfasserin |4 aut | |
| 700 | 1 | |a Manie, Tamer M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Egyptian National Cancer Institute |d Cairo : Inst., 2000 |g 33(2021), 1 vom: 08. Feb. |w (DE-627)546898769 |w (DE-600)2391570-5 |x 2589-0409 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g number:1 |g day:08 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43046-021-00061-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |e 1 |b 08 |c 02 | ||
| author_variant |
m m g y mmg mmgy a a m aa aam t m m tm tmm |
|---|---|
| matchkey_str |
article:25890409:2021----::hipiainoaahlgclopeeepnefhpiayuorfenoduathmteay |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1186/s43046-021-00061-9 doi (DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e DE-627 ger DE-627 rakwb eng 610 ASE Youssef, Mina M. G. verfasserin aut The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 Metwally, Ahmed A. verfasserin aut Manie, Tamer M. verfasserin aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 33(2021), 1 vom: 08. Feb. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:33 year:2021 number:1 day:08 month:02 https://dx.doi.org/10.1186/s43046-021-00061-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2021 1 08 02 |
| spelling |
10.1186/s43046-021-00061-9 doi (DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e DE-627 ger DE-627 rakwb eng 610 ASE Youssef, Mina M. G. verfasserin aut The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 Metwally, Ahmed A. verfasserin aut Manie, Tamer M. verfasserin aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 33(2021), 1 vom: 08. Feb. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:33 year:2021 number:1 day:08 month:02 https://dx.doi.org/10.1186/s43046-021-00061-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2021 1 08 02 |
| allfields_unstemmed |
10.1186/s43046-021-00061-9 doi (DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e DE-627 ger DE-627 rakwb eng 610 ASE Youssef, Mina M. G. verfasserin aut The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 Metwally, Ahmed A. verfasserin aut Manie, Tamer M. verfasserin aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 33(2021), 1 vom: 08. Feb. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:33 year:2021 number:1 day:08 month:02 https://dx.doi.org/10.1186/s43046-021-00061-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2021 1 08 02 |
| allfieldsGer |
10.1186/s43046-021-00061-9 doi (DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e DE-627 ger DE-627 rakwb eng 610 ASE Youssef, Mina M. G. verfasserin aut The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 Metwally, Ahmed A. verfasserin aut Manie, Tamer M. verfasserin aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 33(2021), 1 vom: 08. Feb. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:33 year:2021 number:1 day:08 month:02 https://dx.doi.org/10.1186/s43046-021-00061-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2021 1 08 02 |
| allfieldsSound |
10.1186/s43046-021-00061-9 doi (DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e DE-627 ger DE-627 rakwb eng 610 ASE Youssef, Mina M. G. verfasserin aut The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 Metwally, Ahmed A. verfasserin aut Manie, Tamer M. verfasserin aut Enthalten in Journal of the Egyptian National Cancer Institute Cairo : Inst., 2000 33(2021), 1 vom: 08. Feb. (DE-627)546898769 (DE-600)2391570-5 2589-0409 nnns volume:33 year:2021 number:1 day:08 month:02 https://dx.doi.org/10.1186/s43046-021-00061-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 33 2021 1 08 02 |
| language |
English |
| source |
Enthalten in Journal of the Egyptian National Cancer Institute 33(2021), 1 vom: 08. Feb. volume:33 year:2021 number:1 day:08 month:02 |
| sourceStr |
Enthalten in Journal of the Egyptian National Cancer Institute 33(2021), 1 vom: 08. Feb. volume:33 year:2021 number:1 day:08 month:02 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Neoadjuvant chemotherapy Complete pathological response Management of axilla |
| dewey-raw |
610 |
| isfreeaccess_bool |
true |
| container_title |
Journal of the Egyptian National Cancer Institute |
| authorswithroles_txt_mv |
Youssef, Mina M. G. @@aut@@ Metwally, Ahmed A. @@aut@@ Manie, Tamer M. @@aut@@ |
| publishDateDaySort_date |
2021-02-08T00:00:00Z |
| hierarchy_top_id |
546898769 |
| dewey-sort |
3610 |
| id |
SPR043090869 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR043090869</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519195519.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210209s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43046-021-00061-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR043090869</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)SPRs43046-021-00061-9-e</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43046-021-00061-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Youssef, Mina M. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Complete pathological response</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Management of axilla</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Ahmed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manie, Tamer M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of the Egyptian National Cancer Institute</subfield><subfield code="d">Cairo : Inst., 2000</subfield><subfield code="g">33(2021), 1 vom: 08. Feb.</subfield><subfield code="w">(DE-627)546898769</subfield><subfield code="w">(DE-600)2391570-5</subfield><subfield code="x">2589-0409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">day:08</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43046-021-00061-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="b">08</subfield><subfield code="c">02</subfield></datafield></record></collection>
|
| author |
Youssef, Mina M. G. |
| spellingShingle |
Youssef, Mina M. G. ddc 610 misc Neoadjuvant chemotherapy misc Complete pathological response misc Management of axilla The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| authorStr |
Youssef, Mina M. G. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)546898769 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2589-0409 |
| topic_title |
610 ASE The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery Neoadjuvant chemotherapy (dpeaa)DE-He213 Complete pathological response (dpeaa)DE-He213 Management of axilla (dpeaa)DE-He213 |
| topic |
ddc 610 misc Neoadjuvant chemotherapy misc Complete pathological response misc Management of axilla |
| topic_unstemmed |
ddc 610 misc Neoadjuvant chemotherapy misc Complete pathological response misc Management of axilla |
| topic_browse |
ddc 610 misc Neoadjuvant chemotherapy misc Complete pathological response misc Management of axilla |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of the Egyptian National Cancer Institute |
| hierarchy_parent_id |
546898769 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Journal of the Egyptian National Cancer Institute |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)546898769 (DE-600)2391570-5 |
| title |
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| ctrlnum |
(DE-627)SPR043090869 (DE-599)SPRs43046-021-00061-9-e (SPR)s43046-021-00061-9-e |
| title_full |
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| author_sort |
Youssef, Mina M. G. |
| journal |
Journal of the Egyptian National Cancer Institute |
| journalStr |
Journal of the Egyptian National Cancer Institute |
| lang_code |
eng |
| isOA_bool |
true |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Youssef, Mina M. G. Metwally, Ahmed A. Manie, Tamer M. |
| container_volume |
33 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Youssef, Mina M. G. |
| doi_str_mv |
10.1186/s43046-021-00061-9 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| title_auth |
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| abstract |
Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. |
| abstractGer |
Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. |
| abstract_unstemmed |
Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery |
| url |
https://dx.doi.org/10.1186/s43046-021-00061-9 |
| remote_bool |
true |
| author2 |
Metwally, Ahmed A. Manie, Tamer M. |
| author2Str |
Metwally, Ahmed A. Manie, Tamer M. |
| ppnlink |
546898769 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43046-021-00061-9 |
| up_date |
2024-07-03T16:34:02.611Z |
| _version_ |
1803576349936320512 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR043090869</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519195519.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210209s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43046-021-00061-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR043090869</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)SPRs43046-021-00061-9-e</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43046-021-00061-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Youssef, Mina M. G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy. Results A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups. Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007). Conclusion A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Complete pathological response</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Management of axilla</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Ahmed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manie, Tamer M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of the Egyptian National Cancer Institute</subfield><subfield code="d">Cairo : Inst., 2000</subfield><subfield code="g">33(2021), 1 vom: 08. Feb.</subfield><subfield code="w">(DE-627)546898769</subfield><subfield code="w">(DE-600)2391570-5</subfield><subfield code="x">2589-0409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">day:08</subfield><subfield code="g">month:02</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43046-021-00061-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="b">08</subfield><subfield code="c">02</subfield></datafield></record></collection>
|
| score |
7.4021854 |